| Domain | LDS1 finding | Evidence type/strength | Ontology or identifier |
|---|---|---|---|
| Disease definition | Loeys-Dietz syndrome type 1 (LDS1) is the TGFBR1-related form of Loeys-Dietz syndrome, a syndromic heritable thoracic aortopathy/connective tissue disorder with aggressive aneurysm/dissection risk and extra-aortic craniofacial and skeletal features (pqac-00000001, pqac-00000002, pqac-00000011) | Human clinical + authoritative review; strong for disease entity | MONDO_0018954 (umbrella Loeys-Dietz syndrome); Mendelian disease |
| Causal gene | LDS1 is caused by heterozygous pathogenic variants in **TGFBR1** (transforming growth factor beta receptor 1) (pqac-00000000, pqac-00000001, pqac-00000002, pqac-00000011) | Human genetic evidence + curated disease-target association; strong | TGFBR1; Open Targets disease-target link to MONDO_0018954 |
| Inheritance | Typically **autosomal dominant**; many cases are **de novo** (~75%) and the remainder inherited (~25%), with variable expressivity (pqac-00000002) | Expert review summarizing clinical series; moderate-strong | Autosomal dominant inheritance |
| Variant spectrum | Variants are predominantly **missense substitutions in the kinase domain**; nonsense, frameshift, splice, and deletion variants also occur; germline origin (pqac-00000001, pqac-00000002, pqac-00000011) | Human genetic studies + review; strong for spectrum, limited LDS1-specific frequency data | Germline pathogenic/likely pathogenic variant |
| Main vascular phenotype | Early, progressive **aortic root aneurysm**, widespread arterial tortuosity, aneurysms/dissections throughout the arterial tree, and risk of rupture at relatively small diameters; mitral valve prolapse/regurgitation also common (pqac-00000001, pqac-00000007, pqac-00000008, pqac-00000011) | Human clinical + expert management review + mouse model concordance; strong | HPO terms to consider: Aortic root dilatation, Arterial tortuosity, Aortic dissection, Mitral valve prolapse |
| Craniofacial phenotype | Characteristic features include **hypertelorism**, **bifid uvula/cleft palate**, and sometimes **craniosynostosis**; high-arched palate, micro/retrognathia may occur (pqac-00000006, pqac-00000008) | Expert review from established LDS authorities; moderate-strong | HPO terms to consider: Hypertelorism, Bifid uvula, Cleft palate, Craniosynostosis |
| Skeletal/musculoskeletal phenotype | Common findings include **pectus deformity, scoliosis, pes planus, joint hypermobility**, recurrent subluxations, **camptodactyly/club foot**, cervical spine instability, low bone density, and fracture risk (pqac-00000008) | Expert review; moderate-strong | HPO terms to consider: Pectus excavatum/carinatum, Scoliosis, Pes planus, Joint hypermobility, Camptodactyly, Talipes equinovarus |
| Core mechanism | TGFBR1 mutant cells show impaired response to exogenous TGF-β in vitro, but diseased aortic tissue shows **paradoxically increased SMAD2 phosphorylation and TGF-β target-gene output in vivo**, consistent with compensatory/secondary signaling overdrive during aneurysm progression (pqac-00000010, pqac-00000011, pqac-00000012) | Primary mouse mechanistic study + review; strong mechanistic support with residual uncertainty about upstream trigger | GO terms to consider: TGF-beta receptor signaling pathway, SMAD protein signal transduction |
| Tissue pathology | Aortic wall pathology includes **elastic fiber fragmentation**, **collagen disorganization/excess or defective remodeling**, wall thickening, and altered extracellular matrix homeostasis (pqac-00000003, pqac-00000010, pqac-00000012, pqac-00000013) | Human pathology + primary model systems; strong | GO terms to consider: Extracellular matrix organization, Collagen fibril organization; UBERON: aorta |
| Cell types implicated | **Vascular smooth muscle cells** are central disease cells; evidence also supports roles for aortic root lineage-specific SMC populations and possibly inflammatory/CD45+ cells in signaling amplification (pqac-00000010, pqac-00000013) | Primary mouse and human-cell modeling; moderate-strong | CL terms to consider: vascular smooth muscle cell, endothelial cell, leukocyte |
| Diagnosis | Diagnosis is established by compatible clinical features plus **molecular testing of TGFBR1**; current practice favors **multigene heritable thoracic aortic disease panels**, with CNV analysis if panel-negative (pqac-00000006) | Expert review/current practice; strong | Differential diagnoses include Marfan syndrome, vascular Ehlers-Danlos syndrome, arterial tortuosity syndrome, Shprintzen-Goldberg syndrome |
| Surveillance | Recommended surveillance includes **at least yearly echocardiography** and **head-to-pelvis MRA/CTA** at diagnosis, again at 1 year, then at least every 2–3 years or more often if warranted (pqac-00000007) | Expert management guidance from LDS specialists; strong | Imaging modalities: echocardiography, MRA, CTA |
| Medical treatment | Medical management emphasizes strict blood-pressure control; **ARBs such as losartan** are widely used, often with/against **beta-blockers**. In mouse LDS models, losartan reduced pathologic signaling and improved aortic outcomes (pqac-00000007, pqac-00000009, pqac-00000010, pqac-00000011) | Expert clinical practice + primary preclinical therapeutic evidence; moderate-strong | NCIT terms to consider: Losartan, Beta-Adrenergic Receptor Antagonist Therapy |
| Surgical treatment | **Prophylactic aortic root surgery** is considered at lower thresholds than many other aortopathies; for **LDS1/LDS2, ~4.0 cm** is a commonly cited adult threshold, individualized by growth rate, family history, and valve disease (pqac-00000007) | Expert management guidance; strong but individualized | NCIT terms to consider: Aortic Root Replacement, Valve-Sparing Aortic Root Replacement |
| Lifestyle/prevention | Avoid high-intensity isometric/contact activity and exercise to exhaustion; use caution with vasoconstrictive/stimulant medications. Genetic counseling and family screening are important secondary prevention strategies (pqac-00000007, pqac-00000009) | Expert guidance; moderate-strong | Prevention domains: secondary prevention, cascade genetic screening |
| Prognosis/natural history | Disease is lifelong and progressive, with cardiovascular disease the major cause of morbidity/mortality; vascular events can occur in infancy/childhood or adulthood and at small diameters, so ongoing surveillance is essential (pqac-00000008, pqac-00000011) | Human clinical observation + expert review; strong | Chronic progressive disease course |
| Prevalence caveat | Robust **LDS1-specific prevalence** was not identified in retrieved sources; published estimates usually refer to **all Loeys-Dietz syndrome** (~1 in 100,000), so subtype-specific epidemiology should be treated as uncertain (pqac-00000003) | Review-level estimate; weak for LDS1-specific prevalence | Epidemiology caveat; no confirmed LDS1-only rate |
| Recent QoL/real-world burden | LDS-specific recent data are sparse and often mixed with other HTADs; available studies show reduced physical fitness, fatigue burden, and impaired work participation in mixed LDS cohorts, not LDS1-only samples (pqac-00000014, pqac-00000015, pqac-00000016) | Mixed-cohort observational evidence; limited for LDS1 specificity | PROMIS Fatigue; Satisfaction With Life; disability/work participation |
| Key animal model | **Tgfbr1 M318R/+ knock-in mouse** recapitulates LDS vascular and craniofacial/skeletal phenotypes, unlike simple Tgfbr1 haploinsufficiency; supports pathogenic effect of mutant receptor protein rather than haploinsufficiency alone (pqac-00000011, pqac-00000012) | Primary in vivo model; strong | Mouse knock-in model |
| Key human cellular model | **hiPSC-derived vascular smooth muscle cell/bioengineered vascular graft model with TGFBR1 A230T** shows reduced mechanical strength, in vivo graft dilation, defective ECM gene expression, and decreased collagen hydroxylation (pqac-00000004, pqac-00000013) | Primary translational human model; strong | hiPSC-derived VSMC; bioengineered vascular graft model |
| Current trials landscape | Retrieved records included an **immunopathology** interventional study in genetically confirmed LDS (NCT05472519), but no retrieved **gene therapy/RNA therapy/cell therapy or proven disease-modifying LDS1-specific drug trial** (pqac-00000018) | Clinical trial registry evidence; moderate | NCT05472519 |
| Evidence provenance | This entry is derived from **aggregated disease-level resources**, primary literature, model-system studies, and clinical-trial registries rather than individual EHR data (pqac-00000000, pqac-00000002, pqac-00000018) | Evidence synthesis statement | Disease-level resource provenance |


*Table: This table provides a compact, knowledge-base-ready summary of Loeys-Dietz syndrome type 1 focused on confirmed TGFBR1-related findings, management-relevant features, and model systems. It also flags where evidence is only available for umbrella LDS or mixed cohorts rather than LDS1 specifically.*